Penumbra (PEN) Reported Revenue Growth of 16.9% in Q4

Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here. The fund rose 13.10% (Institutional Shares) in the quarter, compared to a 11.92% gain for the Russell 3000 Health Care Index (benchmark) and a 2.40% gain for the Russell 3000 Index (the Index). The Fund returned 10.28% for the full year, compared to 14.56% and 17.15% gains for the indexes, respectively. Strong stock selection in biotechnology contributed to the Fund’s relative gains in the quarter.  The Fund seeks to invest in businesses with secular growth opportunities, a sustainable competitive edge, and strong management. The firm believes that healthcare is a strong sector in the U.S. economy, offering attractive investment opportunities with positive momentum heading into 2026.  Please review the Fund’s top five holdings to gain insights into their key selections for 2025.

In its fourth-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks like Penumbra, Inc. (NYSE:PEN). Penumbra, Inc. (NYSE:PEN) is a medical device manufacturer that offers peripheral thrombectomy products. On February 5, 2026, Penumbra, Inc. (NYSE:PEN) stock closed at $342.01 per share. One-month return of Penumbra, Inc. (NYSE:PEN) was 6.07%, and its shares are up 31.20% over the past twelve months. Penumbra, Inc. (NYSE:PEN) has a market capitalization of $13.417 billion.

Baron Health Care Fund stated the following regarding Penumbra, Inc. (NYSE:PEN) in its fourth quarter 2025 investor letter:

“Underexposure to the lagging managed health care sub-industry and strong stock selection in health care equipment also added value during the period. Strength in health care equipment primarily came from not owning Index heavyweight Abbott Laboratories. Strong performance from medical device company Penumbra, Inc. (NYSE:PEN) further bolstered outperformance in the sub industry. Penumbra reported strong quarterly financial results in which the company reported 16.9% constant currency revenue growth driven in part by 18.5% U.S. Thrombectomy revenue growth. In early January, the company announced it entered into an agreement to be acquired by Boston Scientific Corporation for approximately $14.5 billion at a 19% premium to the closing price the day prior.”

In another article, we covered Penumbra, Inc. (NYSE:PEN) and shared the list of stocks with remarkable gains. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.